Collaborations and Partnerships

At Biogen Idec, our mission is to discover, develop and deliver to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. We pursue that mission any way we can. So, while we are proud of our ability to develop treatments through our own internal R&D, we are equally committed to alliances, partnerships and collaborations.


Our approach to industry and academic collaborations reflects the same dedication to innovation seen throughout the company. Each collaboration is built on a foundation of mutual respect, aligned interests and a goal of improving the lives of people with serious diseases. We are flexible enough to structure collaborations in ways that make sense for both parties and we work with organizations at all stages in the development process – from discovery collaborations to Phase 3 testing and beyond.

In addition to our industry collaborations, we believe relationships with top academic researchers are critical for maintaining a vibrant and innovative research organization. We have a number of ongoing collaborations with leading research institutions, both individually and in consortia which we have assembled to focus diverse experts on a problem of importance, in which we work together to further understand the causes and potential treatments for complex diseases.


Much of our research pipeline has been built as a result of alliances and collaborations with industry and leading research institutions. We have even collaborated more than once with many of the organizations we work with, proof of the success of these relationships. Among those we work with:

Acorda Therapeutics
Amicus Therapeutics
Eisai Co., Inc.
Galapagos NV
Isis Pharmaceuticals
Neurimmune Therapies AG
NsGene A/S
Portola Pharmaceuticals
Samsung Bioepis
Sangamo BioSciences
Swedish Orphan Biovitrium AB (publ) (Sobi)
UCB S.A., Ltd.

Whitehead Institute/Massachusetts Institute of Technology
Rubin Laboratory /Harvard Medical School
ALS Research Consortium
Duke University and Hudson Alpha Institute for Biotechnology
Lawrence Berkeley National Lab/University of Connecticut Health Center
Scleroderma Consortium